Doravirine/Islatravir Noninferior To Bictegravir/Emtricitabine/Tenofovir Alafenamide As First-Line ART For Patients With HIV, Study Finds

Infectious Disease Advisor (6/2, Nye) reports a study found that “the investigational once-daily regimen of doravirine (DOR) plus islatravir (ISL) was found to be noninferior to bictegravir (BIC) plus emtricitabine (FTC) and tenofovir alafenamide (TAF) through 48 weeks as first-line antiretroviral therapy (ART).” Researchers observed that “at 48 weeks, 88.9% of DOR/ISL recipients and 88.3% of BIC/FTC/TAF recipients achieved HIV suppression, indicating noninferiority between the ART regimens. There was no significant heterogeneity observed in subgroup analyses.” In regard to safety, “most patients experienced AEs, with similar rates observed between DOR/ISL and BIC/FTC/TAF recipients. However, patients in the DOR/ISL cohort exhibited higher rates of infection-related AEs, treatment-related AEs, and severe AEs.” The study was published in Clinical Infectious Diseases.